How Suzetrigine Blocks Pain Signals Without Opioids
Journavx (suzetrigine) is an FDA-approved non-opioid tablet for moderate to severe acute pain in adults. It selectively blocks NaV1.8 sodium channels in peripheral sensory neurons, reducing transmission of pain signals toward the spinal cord and brain.
Timeline
- 2025-01-30: FDA approved Journavx for moderate to severe acute pain in adults.
- At original approval: FDA cited two randomized postoperative efficacy trials and a broader open-label safety study.
- During treatment: The FDA label says use should be for the shortest duration consistent with individual goals and notes that use beyond 14 days was not studied.
Journavx is the brand name for suzetrigine, a prescription sodium-channel blocker that the FDA approved on January 30, 2025, for moderate to severe acute pain in adults. FDA described it as a first-in-class non-opioid analgesic. “Acute” refers to short-term pain, often after tissue injury or surgery; the approval does not make it a general treatment for every pain condition. [1][2]
The drug targets NaV1.8, a voltage-gated sodium channel found in peripheral sensory neurons, including dorsal-root-ganglion neurons. Those channels help generate and carry electrical pain signals. The prescribing information says selective NaV1.8 inhibition reduces transmission of those signals toward the spinal cord and brain. This peripheral sodium-channel mechanism is distinct from activating opioid receptors. [2]
Approval evidence included randomized, double-blind trials after abdominoplasty and bunion surgery. Participants received suzetrigine, placebo or hydrocodone/acetaminophen, and could use specified rescue medication. FDA’s trial snapshot says the program supporting original approval included three trials and 2,447 participants; the third was an open-label safety study covering surgical and nonsurgical acute pain. [2][3]
In both pivotal postoperative trials, the FDA label reports a statistically significant improvement in the 48-hour pain-intensity measure versus placebo. The active-control comparisons need more care: the confidence intervals shown for differences versus hydrocodone/acetaminophen included zero, so those tables do not establish that suzetrigine was superior to the opioid combination. Trial design and population also limit how far the results can be generalized. [2][3]
The label’s recommended adult regimen begins with 100 mg, followed 12 hours later by 50 mg every 12 hours, but dosing can change with liver impairment or interacting medicines. The initial dose has food-timing instructions, and grapefruit is to be avoided. This summary is not a dosing instruction for an individual; patients should follow the prescription label and ask the prescriber or pharmacist about missed doses or interactions. [2]
Safety still matters even though the medicine is non-opioid. The original label lists pruritus, muscle spasms, increased creatine phosphokinase and rash among adverse reactions occurring more often than with placebo. It also contains important CYP3A drug-interaction warnings, contraceptive guidance and recommendations for liver and severe kidney impairment. “Non-opioid” does not mean risk-free or appropriate for self-treatment. [2]
The FDA label says to use Journavx for the shortest duration consistent with individual treatment goals and states that treatment beyond 14 days had not been studied. Anyone considering it should review current medications, pregnancy or contraceptive considerations, liver and kidney status and the cause of pain with a licensed clinician. New or worsening severe pain warrants medical assessment rather than relying on a mechanism explainer. [2]
Sources
- FDA — Approval of a novel non-opioid treatment for moderate to severe acute pain
- FDA — Journavx prescribing information
- FDA — Drug Trials Snapshot: Journavx